Gene polymorphisms of hemostasis and coronary risk;Genpolymorphismen der hämostase und koronarrisiko

Medizinische Klinik

Volumn 96, Issue 4, 2001, Pages 217-227

  Hellstern, Peter ^a   Bach, Jürgen ^a   Haubelt, Hannelore ^a   Preiss, Alexandra ^a   Winkelmann, Bernhard Rudolf ^a   Senges, Jochen ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Acute coronary syndromes; Coronary heart disease; Coronary risk; Gene polymorphisms; Hemostasis

Indexed keywords

FIBRINOGEN; PROTHROMBIN;

CORONARY RISK; DNA POLYMORPHISM; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; REVIEW; RISK FACTOR;

EID: 0035871113     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002197     Document Type: Review

References (81)

1. Prothrombotic genetic risk factors in young survivors of myocardial infarction
2. Glycoprotein la gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting
3. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction
4. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction
5. (A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen beta 448 polymorphism with myocardial infarction and extent of coronary artery disease
6. The FXIII Va134Leu polymorphism in venous and arterial thromboembolism
7. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study
8. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: Proposed role for all acute-phase reaction pattern of fibrinogen
9. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
10. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A
11. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men
12. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease
13. Ischemic heart disease and platelet aggregation
14. A2 polymorphism: The Framingham Offspring Study
15. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: The Framingham Heart Study
16. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
17. Factor XIII va134leu and the risk of myocardial infarction
18. Genetic and environmental sources of fibrinogen variability in Israeli families: The Kibbutzim Family Study
19. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease
20. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease
21. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction
22. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
23. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease
24. Polymorphisms of platelet membrane glycoprotein lb associated with arterial thrombotic disease
25. A2. Zwb) positive platelets in patients with cardiovascular disease
26. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
27. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men
28. Étude cas-témoins de l'Infarctus du myocarde
29. European Atherosclerosis Research Study: Genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe
30. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A recta-analysis
31. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction
32. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease
33. Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease
34. Plasminogen-activator inhibitor type 1 and coronary artery disease
35. Association of a common polymorphism in the factor XIII gene with myocardial infarction
36. The impact of the glycoprotein la collagen receptor subunit A1648G gene polymorphism on coronary artery disease and acute myocardial infarction
37. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
38. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence
39. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study
40. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
41. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: A case-controlled study
42. Molecular diagnosis of inherited bleeding disorders and thrombophilia
43. Atherosclerosis
44. Haemostatic function, arterial disease and the prevention of arterial thrombosis
45. Cardiovascular implications of the factor V Leiden mutation
46. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease
47. Influence of platelet size on outcome after myocardial infarction
48. Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD)
49. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
50. Thrombosis Prevention Trial: Randomised trial of low-intensity oral anticoagulation with warfarin low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
51. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease
52. Association of two silent polymorphisms of platelet glycoprotein 1a/11a receptor with risk of myocardial infarction: A case-control study
53. Prothrombin G20210A polymorphism and thrombophilia
54. Review and management of patients with the prothrombin G20210A polymorphism
55. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
56. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
57. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis
58. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
59. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
60. Association of the platelet glycoprotein la C807T gene polymorphism with nonfatal myocardial infarction in younger patients
61. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
62. Diagnosis and management of inherited and acquired thrombophilias
63. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects
64. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men
65. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
66. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: Results from the Cardiovascular Health Study
67. Platelet hyperreactivity and prognosis in survivors of myocardial infarction
68. A common mutation (G-455→A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study
69. Circulating factors of the haemostatic systems as indicators of increased or reduced corollary, risk
70. Tissue plasminogen activator and risk of myocardial infarction
71. Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease?
72. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis
73. Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary, artery, disease
74. Association of FXIII VaI34Leu with decreased risk of myocardial infarction in Finnish males
75. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
76. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease
77. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study
78. Genetics of coronary heart disease: Current knowledge and research principles
79. Étude Cas-Témoins de l'Infarctus du Myocarde
80. A2) is a risk factor for bypass occlusion, myocardial infarction, and death
81. A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease